Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2051 and Irinotecan Hydrochloride Liposome in Advanced Solid Tumors
NCT07911579Phase 2Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SYH2051 in solid tumor, sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose-Limiting Toxicity, Adverse Events and 3 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
SYH2051
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07911579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07911579.